Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

After a years-long revenue drought, there's a light at the end of the tunnel.

But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its effectiveness in another group of patients with the bleeding disorder. That's ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

The Trump administration is delaying the release of TrumpRx, an online platform that lets people buy prescription drugs ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Add Yahoo as a preferred source to see more of our stories on Google. U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla, on the day he announces a deal with Pfizer to sell drugs ...

The MarketWatch News Department was not involved in the creation of this content. SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, ...

In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving ...